GW Pharma (NASDAQ:GWPH) is a NASDAQ-traded biotech based in the UK with a primary listing on the London Stock Exchange (GWP is the symbol). After trading quietly for months following its May 1st IPO, the stock has more than tripled. Though it has traded publicly since 2001 without much success, the recent move following an analyst upgrade and dramatic target hike pushed the stock to a multi-year high. The move earlier this year to gain a U.S. listing was brilliant, as it has expanded the investor base and more than doubled its analyst following. GW has done a lot of things correctly in my view, and it is poised to benefit from increased investor awareness of its opportunities....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|